The researchers conclude that targeting the metabolic changes in tRCC, specifically through inhibiting PPARGC1A-mediated mitochondrial respiration, offers a new treatment approach. Here, PPARGC1A is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.